Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired Severe Aplastic Aplasia Receiving Single Cord Blood Transplant: A Multi-center, Single-arm Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaoyu Zhu, ph.D
- Phone Number: 15255456091
- Email: xiaoyuz@ustc.edu.cn
Study Contact Backup
- Name: Baolin Tang, M.D
- Phone Number: 13856901277
- Email: zwcrystalbl@163.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230036
- Recruiting
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
-
Contact:
- Xiaoyu Zhu, ph.D
- Phone Number: 15255456091
- Email: xiaoyuz@ustc.cn
-
Contact:
- Baolin Tang, M.D
- Phone Number: 13856901277
- Email: zwcrystalbl@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with severe aplastic anemia who do not respond to initial diagnosis or immunosuppressive therapy;
- Patients meet diagnostic criteria for severe aplastic anemia (Camitta criteria);
- Age from 1 to 50 years old, male or female;
- Patients without HLA-matched sibling or unrelated donors avaliable;
- Patients who have undergone unrelated cord blood transplantation need to have HLA high-resolution matching、TNC (before cord blood freezing)≥3.0×107/kg、CD34+(before cord blood freezing)≥1.5×107/kg、tubule recovery rate≥80%;
- patients and their family members or guardians agreed to the study and signed informed consent;
- No severe organ failure;
- ECOG score≤2 and HCT-CI≤2;
- serum ferritin (SF)<1000ug/L;
- women of reproductive agemust have a negative pregnancy test and agree to use effective contraception during treatment and for one year thereafter.
Exclusion Criteria:
- patients with inherited bone marrow failure syndromes;
- Positive for HLA-A, B, Cw, DRB1, DQB1, DPB1 site-specific HLA antibodies for donor cord blood with solid-phase fluorescence assay;
- patients who have previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- Uncontrolled bacterial, viral, or fungal infections;
- HIV infection or active viral hepatitis B or C infection;
- Pregnant or breastfeeding women;
- patients with a history of primary malignancy within 3 years prior to transplant treatment;
- patients receiving ATG treatment within 2 weeks before transplantation;
- patients with drug dependent or uncontrolled mental illness or cognitive impairment;
- Participants in other similar clinical studies within 3 months;
- Patients allergic to ATG;
- patients considered unsuitable for inclusion by the researchers.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ATG group
Patients in the ATG group will be treated with conditioning regimen containing ATG 2mg/kg on day -7 prior to transplant.
|
Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The one-year probability of GRFS
Time Frame: one year
|
GRFS is defined as survival without grade III-IV acute GVHD immunosuppression requiring chronic GVHD or relapse.
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The cumulative incidence of platelet engraftment at 28 days after transplantation
Time Frame: 28 days
|
Platelet engraftment is defined as independent from platelet transfusion for at least 7 days with a platelet count of more than 20 × 10^9/L.
|
28 days
|
|
The cumulative incidence of neutrophil engraftment at 28 days after transplantation
Time Frame: 28 days
|
Neutrophil engraftment is defined as neutrophil count achieves 0.5 ×10^9/L for three consecutive days.
|
28 days
|
|
Time of platelet engraftment
Time Frame: 28 days
|
Platelet engraftment is defined as independent from platelet transfusion for at least 7 days with a platelet count of more than 20 × 10^9/L.
|
28 days
|
|
Time of neutrophil engraftment
Time Frame: 28 days
|
Neutrophil engraftment is defined as neutrophil count achieves 0.5 ×10^9/L for three consecutive days.
|
28 days
|
|
The cumulative incidence of acute GVHD at 100 days after transplantation
Time Frame: 100 days
|
Acute GVHD is defined that occurs within 100 days after transplantation
|
100 days
|
|
The cumulative incidence of chronic GVHD at 100 days after transplantation
Time Frame: one year
|
Chronic GVHD is defined that occurs 100 days after transplantation
|
one year
|
|
Immune reconstitution after transplantation
Time Frame: one year
|
The level of immunoglobulin, T cells, B cells and NK cells reconstitution after transplantation
|
one year
|
|
The 180-day probability of TRM
Time Frame: 180 days
|
TRM(transplant-related mortality) is defined that death due to any transplant-related cause within 180 days after transplantation
|
180 days
|
|
The incidence of infection
Time Frame: one year
|
Infection is defined as various post-transplant associated infections
|
one year
|
|
The one-year probability of OS
Time Frame: one year
|
OS (overall survival) is defined as the time which begins at diagnosis and up to the time of death
|
one year
|
|
The one-year probability of DFS
Time Frame: one year
|
DFS (disease free survival) is defined as the time from treatment until the recurrence of disease (or death) after transplantation
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xiaoyu Zhu, ph.D, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CBSAA001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.